{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:11:12Z","timestamp":1759482672528},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2009,5,8]],"date-time":"2009-05-08T00:00:00Z","timestamp":1241740800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hypertens Res"],"published-print":{"date-parts":[[2009,7]]},"DOI":"10.1038\/hr.2009.61","type":"journal-article","created":{"date-parts":[[2009,5,8]],"date-time":"2009-05-08T08:37:49Z","timestamp":1241771869000},"page":"604-610","source":"Crossref","is-referenced-by-count":10,"title":["Telmisartan predominantly suppresses cardiac fibrosis, rather than hypertrophy, in renovascular hypertensive rats"],"prefix":"10.1038","volume":"32","author":[{"given":"Makoto","family":"Kawai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenichi","family":"Hongo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimiaki","family":"Komukai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Morimoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Makoto","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shingo","family":"Seki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seibu","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michihiro","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2009,5,8]]},"reference":[{"key":"BFhr200961_CR1","doi-asserted-by":"publisher","first-page":"1431","DOI":"10.1056\/NEJM199405193302008","volume":"330","author":"GH Gibbons","year":"1994","unstructured":"Gibbons GH, Dzau VJ . The emerging concept of vascular remodeling. N Engl J Med 1994; 330: 1431\u20131438.","journal-title":"N Engl J Med"},{"key":"BFhr200961_CR2","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1006\/jmcc.2002.2075","volume":"34","author":"J Varagic","year":"2002","unstructured":"Varagic J, Frohlich ED . Local cardiac renin\u2013angiotensin system: hypertension and cardiac failure. J Mol Cell Cardiol 2002; 34: 1435\u20131442.","journal-title":"J Mol Cell Cardiol"},{"key":"BFhr200961_CR3","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1016\/S0140-6736(02)08089-3","volume":"359","author":"B Dahlof","year":"2002","unstructured":"Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H . Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995\u20131003.","journal-title":"Lancet"},{"key":"BFhr200961_CR4","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/S0140-6736(00)02213-3","volume":"355","author":"B Pitt","year":"2000","unstructured":"Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B . Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial\u2014the Losartan Heart Failure Survival Study II ELITE. Lancet 2000; 355: 1582\u20131587.","journal-title":"Lancet"},{"key":"BFhr200961_CR5","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1067\/mhj.2000.111112","volume":"140","author":"DW Brown","year":"2000","unstructured":"Brown DW, Giles WH, Croft JB . Left ventricular hypertrophy as a predictor of coronary heart disease mortality and the effect of hypertension. Am Heart J 2000; 140: 848\u2013856.","journal-title":"Am Heart J"},{"key":"BFhr200961_CR6","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1161\/01.HYP.33.4.981","volume":"33","author":"V Robert","year":"1999","unstructured":"Robert V, Heymes C, Silvestre JS, Sabri A, Swynghedauw B, Delcayre C . Angiotensin AT1 receptor subtype as a cardiac target of aldosterone: role in aldosterone-salt-induced fibrosis. Hypertension 1999; 33: 981\u2013986.","journal-title":"Hypertension"},{"key":"BFhr200961_CR7","doi-asserted-by":"publisher","first-page":"S95","DOI":"10.1097\/00004872-199609002-00018","volume":"14","author":"T Unger","year":"1996","unstructured":"Unger T, Chung O, Csikos T, Culman J, Gallinat S, Gohlke P, Hohle S, Meffert S, Stoll M, Stroth U, Zhu YZ . Angiotensin receptors. J Hypertens Suppl 1996; 14: S95\u2013S103.","journal-title":"J Hypertens Suppl"},{"key":"BFhr200961_CR8","doi-asserted-by":"publisher","first-page":"1952","DOI":"10.1161\/01.CIR.97.19.1952","volume":"97","author":"K Harada","year":"1998","unstructured":"Harada K, Komuro I, Shiojima I, Hayashi D, Kudoh S, Mizuno T, Kijima K, Matsubara H, Sugaya T, Murakami K, Yazaki Y . Pressure overload induces cardiac hypertrophy in angiotensin II type 1A receptor knockout mice. Circulation 1998; 97: 1952\u20131959.","journal-title":"Circulation"},{"key":"BFhr200961_CR9","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1161\/01.HYP.0000123072.34629.57","volume":"43","author":"SC Benson","year":"2004","unstructured":"Benson SC, Pershadsingh HA, Ho CI, Chittiboyina A, Desai P, Pravenec M, Qi N, Wang J, Avery MA, Kurtz TW . Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPARgamma-modulating activity. Hypertension 2004; 43: 993\u20131002.","journal-title":"Hypertension"},{"key":"BFhr200961_CR10","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s10557-005-5059-7","volume":"18","author":"M Nagai","year":"2004","unstructured":"Nagai M, Horikoshi K, Izumi T, Seki S, Taniguchi M, Taniguchi I, Mochizuki S . Cardioprotective action of perindopril versus candesartan in renovascular hypertensive rats. Cardiovasc Drugs Ther 2004; 18: 353\u2013362.","journal-title":"Cardiovasc Drugs Ther"},{"key":"BFhr200961_CR11","first-page":"H1824","volume":"273","author":"M Obayashi","year":"1997","unstructured":"Obayashi M, Yano M, Kohno M, Kobayashi S, Tanigawa T, Hironaka K, Ryouke T, Matsuzaki M . Dose-dependent effect of ANG II-receptor antagonist on myocyte remodeling in rat cardiac hypertrophy. Am J Physiol 1997; 273: H1824\u2013H1831.","journal-title":"Am J Physiol"},{"key":"BFhr200961_CR12","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1161\/hy0202.103417","volume":"39","author":"JL Zhuo","year":"2002","unstructured":"Zhuo JL, Mendelsohn FA, Ohishi M . Perindopril alters vascular angiotensin-converting enzyme, AT(1) receptor, and nitric oxide synthase expression in patients with coronary heart disease. Hypertension 2002; 39: 634\u2013638.","journal-title":"Hypertension"},{"key":"BFhr200961_CR13","doi-asserted-by":"publisher","first-page":"865","DOI":"10.1291\/hypres.27.865","volume":"27","author":"Y Tanaka","year":"2004","unstructured":"Tanaka Y, Nagai M, Date T, Okada T, Abe Y, Seki S, Taniguchi M, Taniguchi I, Mochizuki S . Effects of bradykinin on cardiovascular remodeling in renovascular hypertensive rats. Hypertens Res 2004; 27: 865\u2013875.","journal-title":"Hypertens Res"},{"key":"BFhr200961_CR14","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1006\/jmcc.1993.1002","volume":"25","author":"N Ito","year":"1993","unstructured":"Ito N, Isoyama S, Takahashi T, Takishima T . Coronary dilator reserve and morphological changes after relief of pressure-overload in rats. J Mol Cell Cardiol 1993; 25: 3\u201314.","journal-title":"J Mol Cell Cardiol"},{"key":"BFhr200961_CR15","first-page":"1163","volume":"12","author":"JB O'Sullivan","year":"1994","unstructured":"O'Sullivan JB, Black MJ, Bertram JF, Bobik A . Cardiovascular hypertrophy in one-kidney, one clip renal hypertensive rats: a role for angiotensin II? J Hypertens 1994; 12: 1163\u20131170.","journal-title":"J Hypertens"},{"key":"BFhr200961_CR16","doi-asserted-by":"publisher","first-page":"1328","DOI":"10.1139\/y97-163","volume":"75","author":"LS Matsubara","year":"1997","unstructured":"Matsubara LS, Matsubara BB, Okoshi MP, Franco M, Cicogna AC . Myocardial fibrosis rather than hypertrophy induces diastolic dysfunction in renovascular hypertensive rats. Can J Physiol Pharmacol 1997; 75: 1328\u20131334.","journal-title":"Can J Physiol Pharmacol"},{"key":"BFhr200961_CR17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/ajh.2008.27","volume":"21","author":"N Kobayashi","year":"2008","unstructured":"Kobayashi N, Ohno T, Yoshida K, Fukushima H, Mamada Y, Nomura M, Hirata H, Machida Y, Shinoda M, Suzuki N, Matsuoka H . Cardioprotective mechanism of telmisartan via PPAR-gamma-eNOS pathway in dahl salt-sensitive hypertensive rats. Am J Hypertens 2008; 21: 576\u2013581.","journal-title":"Am J Hypertens"},{"key":"BFhr200961_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1097\/FJC.0b013e318169e948","volume":"51","author":"B Liang","year":"2008","unstructured":"Liang B, Leenen FH . Prevention of salt-induced hypertension and fibrosis by AT1-receptor blockers in Dahl S rats. J Cardiovasc Pharmacol 2008; 51: 457\u2013466.","journal-title":"J Cardiovasc Pharmacol"},{"key":"BFhr200961_CR19","doi-asserted-by":"publisher","first-page":"117","DOI":"10.3317\/jraas.2001.012","volume":"2","author":"PJ Lijnen","year":"2001","unstructured":"Lijnen PJ, Petrov VV, Fagard RH . Angiotensin II-induced stimulation of collagen secretion and production in cardiac fibroblasts is mediated via angiotensin II subtype 1 receptors. J Renin Angiotensin Aldosterone Syst 2001; 2: 117\u2013122.","journal-title":"J Renin Angiotensin Aldosterone Syst"},{"key":"BFhr200961_CR20","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cardiores.2006.07.014","volume":"72","author":"I Imayama","year":"2006","unstructured":"Imayama I, Ichiki T, Inanaga K, Ohtsubo H, Fukuyama K, Ono H, Hashiguchi Y, Sunagawa K . Telmisartan downregulates angiotensin II type 1 receptor through activation of peroxisome proliferator-activated receptor gamma. Cardiovasc Res 2006; 72: 184\u2013190.","journal-title":"Cardiovasc Res"},{"key":"BFhr200961_CR21","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1161\/01.HYP.26.6.971","volume":"26","author":"V Robert","year":"1995","unstructured":"Robert V, Silvestre JS, Charlemagne D, Sabri A, Trouve P, Wassef M, Swynghedauw B, Delcayre C . Biological determinants of aldosterone-induced cardiac fibrosis in rats. Hypertension 1995; 26: 971\u2013978.","journal-title":"Hypertension"},{"key":"BFhr200961_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1097\/00004872-200405000-00025","volume":"22","author":"A Tanabe","year":"2004","unstructured":"Tanabe A, Naruse M, Hara Y, Sato A, Tsuchiya K, Nishikawa T, Imaki T, Takano K . Aldosterone antagonist facilitates the cardioprotective effects of angiotensin receptor blockers in hypertensive rats. J Hypertens 2004; 22: 1017\u20131023.","journal-title":"J Hypertens"},{"key":"BFhr200961_CR23","doi-asserted-by":"publisher","first-page":"1175","DOI":"10.1006\/jmcc.1999.0963","volume":"31","author":"SH Slight","year":"1999","unstructured":"Slight SH, Joseph J, Ganjam VK, Weber KT . Extra-adrenal mineralocorticoids and cardiovascular tissue. J Mol Cell Cardiol 1999; 31: 1175\u20131184.","journal-title":"J Mol Cell Cardiol"},{"key":"BFhr200961_CR24","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J . The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709\u2013717.","journal-title":"N Engl J Med"},{"key":"BFhr200961_CR25","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1536\/ihj.47.783","volume":"47","author":"T Okada","year":"2006","unstructured":"Okada T, Nagai M, Taniguchi I, Kuno M, Imamoto S, Seki S, Taniguchi M, Mochizuki S . Combined treatment with valsartan and spironolactone prevents cardiovascular remodeling in renovascular hypertensive rats. Int Heart J 2006; 47: 783\u2013793.","journal-title":"Int Heart J"},{"key":"BFhr200961_CR26","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1530\/acta.0.1220369","volume":"122","author":"H Sasamura","year":"1990","unstructured":"Sasamura H, Suzuki H, Kato R, Saruta T . Effects of angiotensin II, ACTH, and KCl on the adrenal renin\u2013angiotensin system in the rat. Acta Endocrinol (Copenh) 1990; 122: 369\u2013373.","journal-title":"Acta Endocrinol (Copenh)"},{"key":"BFhr200961_CR27","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1161\/01.HYP.0000022606.52221.2F","volume":"40","author":"M Naruse","year":"2002","unstructured":"Naruse M, Tanabe A, Sato A, Takagi S, Tsuchiya K, Imaki T, Takano K . Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension 2002; 40: 28\u201333.","journal-title":"Hypertension"},{"key":"BFhr200961_CR28","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1161\/01.CIR.100.10.1056","volume":"100","author":"RS McKelvie","year":"1999","unstructured":"McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, Tsuyuki RT, White M, Rouleau J, Latini R, Maggioni A, Young J, Pogue J . Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999; 100: 1056\u20131064.","journal-title":"Circulation"},{"key":"BFhr200961_CR29","doi-asserted-by":"publisher","first-page":"2981","DOI":"10.1001\/jama.288.23.2981","volume":"288","author":"ALLHAT Collaborative Research Group","year":"2002","unstructured":"ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981\u20132997.","journal-title":"JAMA"}],"container-title":["Hypertension Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/hr200961.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr200961","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/hr200961.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T17:04:55Z","timestamp":1684429495000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/hr200961"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,5,8]]},"references-count":29,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2009,7]]}},"alternative-id":["BFhr200961"],"URL":"https:\/\/doi.org\/10.1038\/hr.2009.61","relation":{},"ISSN":["0916-9636","1348-4214"],"issn-type":[{"value":"0916-9636","type":"print"},{"value":"1348-4214","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,5,8]]}}}